

Bisphosphonate Related Osteonecrosis of Maxilla Following Implant Failure – A Case Report

Dr. Vijay Ebenezer, Dr. Balakrishnan

Professor and Head of Department Oral and Maxillofacial surgery Sree balaji dental college and hospital Pallikaranai, Chennai – 100

Abstract:

Marx in the year 2003, defined osteonecrosis of the jaw (ONJ) as exposed, necrotic bone in the maxillofacial region for at least eight weeks in patients receiving anti-resorptive medication for primary or metastatic bone cancer, osteoporosis or Paget's disease, without history of radiation therapy to the jaws¹. The AAOMS, modified the above definition to include exposed bone, or bone that can be probed through an intra oral or extra oral fistula in patients who are on antiresorptive or anti angiogenic medications².

Bisphosphonates treatment has been found to be a major factor contributing to the development of osteonecrosis of the jaws. Bisphosphonate related osteonecrosis of the jaws is the most common side effect of bisphosphonate treatment, without previous history of radiation therapy to the jaws¹. According to Kurtzman, it is considered to be a long term and irreversible, even on discontinuation of drugs³.

INTRODUCTION:

Marx in the year 2003, defined osteonecrosis of the jaw (ONJ) as exposed, necrotic bone in the maxillofacial region for at least eight weeks in patients receiving anti-resorptive medication for primary or metastatic bone cancer, osteoporosis or Paget's disease, without history of radiation therapy to the jaws¹. The AAOMS, modified the above definition to include exposed bone, or bone that can be probed through an intra oral or extra oral fistula in patients who are on antiresorptive or anti angiogenic medications².

Bisphosphonates treatment has been found to be a major factor contributing to the development of osteonecrosis of the jaws. Bisphosphonate related osteonecrosis of the jaws is the most common side effect of bisphosphonate treatment, without previous history of radiation therapy to the jaws¹. According to Kurtzman, it is considered to be a long term and irreversible, even on discontinuation of drugs³.

As mentioned by Ruggiero et al., osteonecrosis of the jaw occurs more in the mandible and less in the maxilla⁴. The reason for this being good vascularisation and high bone turnover rate in the maxilla. Hence, maxillary ONJ lesions are extremely rare.

The possibility to perform dental extractions and dental implant placement in bisphosphonate or anti resorptive agent users, continues to be a controversy. The American Association of oral and maxillofacial surgeons contraindicate implant surgery in patients who are under anti-resorptive therapy².

This article reports the rare occurrence of osteonecrosis of the maxilla associated with implant failure in a patient who underwent bisphosphonate therapy.

CASE REPORT :

A 48 year old male patient , reported to Sree Balaji Dental College and hospital , Chennai . The patient complained of swelling , pain and burning sensation in the maxilla for 1 month .

The patient had a history of osteoporosis for the past 2 years and was under bisphosphonate therapy . All on four implants were placed in the maxilla 1 year back , the prosthetic rehabilitation was also completed , at a private dental clinic .

On examination , extra orally – no abnormality was detected . Intra orally , a firm swelling was observed in the maxillary region , upto the hard palate . Necrosed maxillary bone was exposed . The implants and the prosthesis were mobile . It was also observed that the implants were exposed .

Local anaesthesia was administered and the prosthesis was removed , as the first step . The following (FIG. 1)is the intra oral picture after the removal of the prosthesis .



FIG 1: NECROSED MAXILLARY BONE AND EXPOSED DENTAL IMPLANTS

A crestal incision was placed extending from 17 to 27 region . Mucoperiosteal flap was elevated (FIG 2 &3). The dental implants were removed . Sequestrum was removed (FIG. 3) . Debridement and curettage was done . Thorough metrogyl irrigation was carried out . Primary closure was done with silk suture (FIG. 4) .



FIGURE 2




FIGURE 3




FIGURE 3

FIGURE 4

The patient was then administered with antibiotics and anti inflammatory medications . Review was done on the fifth and seventh post operative day .

DISCUSSION :

The patient had a history of taking Alendronate for 2 years , when he had presented for implant placement in the maxilla at a private dental clinic . The presence of clinically visible necrosed bone in the maxilla ,mobile dental implants , chronic pain and burning sensation in the maxilla , as observed during examination of the patient , was suggestive of stage II Bisphosphonate related osteonecrosis of the jaw (BONJ) , as per the staging system given by Ruggiero et al⁵. The histopathological report confirmed the same .

As mentioned by Petropoulous et al. , several studies quote that there is a decreased incidence of osteonecrosis when the patient has been on oral bisphosphonate therapy for less than five years ⁶. In a study conducted by Fuggazo et al. ⁷, it was concluded that patients who were on bisphosphonate therapy for an average duration of 3.3 years , did not experience any incidence of osteonecrosis following implant placement in intact alveolar ridges or following immediate implant placement after tooth extractions . Another study by Madrid and Sanz ⁸, stated that no BONJ was observed in patients who took bisphosphonates for less than 5 years . Hence , the case reported in this article is a rare incident , as the patient ws on bisphosphonates for only 2 years .

A detailed treatment protocol was laid down by Rugeeiro et al. for evert stage of bisphosphonate related osteonecrosis of the jaw . It was stated that for stage III disease , as seen in this case , surgical debridement of necrotic bone ,followed by antimicrobial therapy , analgesics and anitmicrobial rinses is the best treatment protocol ⁷. As per the prescribed treament protocol , surgical debridement was carried out for this patient , followed by medication , after the culture results were obtained .

CONCLUSION :

In conclusion , although bisphosphonate related osteonecrosis of the jaw is not encountered very often , it is essential that the diagnosis and management of this condition is known by

every oral and maxillofacial surgeon . A complete history must be taken by the oral surgeon , before placement of dental implants , so as to avoid the failure of implants .

REFERENCES:

- 1) Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. *J Oral Maxillofac Surg.* 2003;61:1115–1117.
- 2) Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons. Position paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. *J Oral Maxillofac Surg.* 2014;72: 1938–1956.
- 3) Kurtzman, GM, Silverstein LH, Peden J, Shatz PC. Implications of bisphosphonate use for the dentist: an introduction. *Dent Today.* 2006;25: 80–85.
- 4) Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw-2014 Update. *J Oral Maxillofac Surg.* 2014;72:1938.
- 5) Ruggiero , John Fantasia , Eric Carlson et al. Oral surgery , Oral Medicine , Oral Pathology , Oral Radiology and Oral Endodontology . 2006 ; vol.102, No.4.
- 6) Petropoulos , Balshi, Wolfinger et al. Patient with implant failure and jaw osteonecrosis : Successful retreatment using implants . *Journal of Oral Implantology.* Vol. XLII / No. 1/ 216 .
- 7) Fuggazato PA, Lightfoot SW, Jaffin R, Kumar A. Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow-up, and the incidence of complications in two private practices. *J Periodontol.* 2007;78:1664–1669.
- 8) Madrid C, Sanz M. What impact do systematically administered bisphosphonates have on oral implant therapy? A systematic review. *Clin Oral Implants Res.* 2009;20:87–95.